Indeed, Pritchard et al. determined that many metastatic prostate cancer patients had DNA-repair gene mutations such as BRCA1, BRCA2, ATM, CHEK1/2, RAD51 [31] and that these mutations were present in 11.8% of prostate cancer patients. Here, CHEK1 is linked to prostate carcinoma.